オプションチェーンは、AstraZenecaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、AstraZenecaの市場センチメントを評価します。.

AstraZeneca (NASDAQ:AZN) 株価情報, オプションチェーン

AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AstraZeneca PLC - American Depositary Shares

AstraZeneca PLC

ASTRAZENECA ORD

AstraZeneca PLC ADRhedged AstraZeneca PLC ADRhedged

AZN Capital Corp

Investors with a lot of money to spend have taken a bullish stance on AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AZN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for AstraZeneca.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $606,896, and 13 are calls, for a total amount of $967,112.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $74.0 for AstraZeneca over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for AstraZeneca's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across AstraZeneca's significant trades, within a strike price range of $30.0 to $74.0, over the past month.
<h3>AstraZeneca Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730746825_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.53</td>
<td>$2.45</td>
<td>$2.55</td>
<td>$70.00</td>
<td>$462.2K</td>
<td>5.1K</td>
<td>1.8K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$42.0</td>
<td>$41.75</td>
<td>$41.75</td>
<td>$30.00</td>
<td>$263.0K</td>
<td>72</td>
<td>63</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$22.75</td>
<td>$22.4</td>
<td>$22.4</td>
<td>$50.00</td>
<td>$141.1K</td>
<td>7</td>
<td>73</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$18.05</td>
<td>$17.6</td>
<td>$17.6</td>
<td>$55.00</td>
<td>$110.8K</td>
<td>28</td>
<td>63</td>
</tr>
<tr>
<td>AZN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.5</td>
<td>$2.47</td>
<td>$2.5</td>
<td>$70.00</td>
<td>$108.0K</td>
<td>5.1K</td>
<td>1.8K</td>
</tr>
</tbody>
</table>

<h3>About AstraZeneca</h3>
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
After a thorough review of the options trading surrounding AstraZeneca, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>AstraZeneca's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 5,949,833, the AZN's price is up by 0.04%, now at $71.44. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 8 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AstraZeneca options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Smart Money Is Betting Big In AZN Options

At the ObesityWeek 2024, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) shared data abstracts highlighting early data from AZD5004/ECC5004.
In November 2023, AstraZeneca announced an exclusive license agreement with&nbsp;Eccogene&nbsp;for potential obesity treatment, ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist.
Eccogene received an initial upfront <a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35694148/astrazeneca-joins-anti-obesity-race-dominated-by-eli-lilly-and-novo-nordisk-reports-mixed-q3-earn" rel="noreferrer noopener">payment of $185 million</a>.&nbsp;In addition, Eccogene will also receive up to an additional $1.825 billion in future milestone payments.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38055367/astrazeneca-ceo-highlights-decade-long-sales-goal-of-45b-along-with-investor-doubts-as-it-lags-in" rel="noreferrer noopener">AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race</a>
The company shared <a target="_blank" href="https://tos.planion.com/Web.User/AbstractDet?ACCOUNT=TOS&amp;ABSID=1084817&amp;CONF=OW2024&amp;ssoOverride=OFF&amp;CKEY=3Y2451613" rel="noreferrer noopener">data</a> from a double-blind, randomized, placebo-controlled study of ECC5004 in healthy participants in single doses (SAD) and participants with type 2 diabetes (T2DM) on metformin only and in multiple doses (MAD). The primary objective was to evaluate safety and tolerability.
In the SAD, 19 randomized participants received eight doses ranging from 1mg to 300mg.There were no serious adverse events (AEs), and gastrointestinal (GI) AEs were most common in doses ≥ 50mg.
Pharmacokinetic (PK) profiles demonstrated a linear profile and geometric mean half-life of between 11.06h (CV 14.2%) to 24.48h (CV 9.3%) and Tmax of 7.6h (CV 36.68) to 16.7 h (CV 101).
The researchers note that this first-in-human study demonstrated that ECC5004 has a safety and tolerability profile consistent with that observed for other small molecule GLP-1RAs and a PK profile compatible with once-daily dosing.
Changes in glucose levels and body weight suggest ECC5004 achieved target engagement of the GLP-1R.
Data from an open-label, randomized, single-dose cross-over study in 14 healthy participants under fasted/fed conditions showed that AZD5004/ECC5004 may be <a target="_blank" href="https://tos.planion.com/Web.User/AbstractDet?ACCOUNT=TOS&amp;ABSID=1089318&amp;CONF=OW2024&amp;ssoOverride=OFF&amp;CKEY=3Y2451613" rel="noreferrer noopener">administered</a> orally in the fasted or fed state as overall exposure and T1/2 are unaffected by food, suggesting that AZD5004/ECC5004 has the potential to be a more convenient, oral, once-daily therapy for patients.
The researchers added that prolonged Tmax, and lower Cmax observed in the fed state have the potential to confer better tolerability, but this will need to be evaluated in larger and longer studies, which are currently in progress.
Price Action: AZN stock is up 0.04% at $71.45&nbsp;at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41720954/disney-creates-new-tech-hub-for-ai-and-ar" target="_blank" rel="noreferrer noopener">Disney Creates New Tech Hub For AI and AR</a></li>
</ul>

Biotech

Large Cap

News

Health Care

General

AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug

<h3>https://www.astrazeneca.com/investor-relations/meet-the-management-weight-management-virtual-event.html</h3>
<h3>&nbsp;</h3>
<h3>AstraZeneca will recap recent preclinical and Phase I data across its weight management pipeline. The accompanying slides and replay&nbsp;will be available on November 5, 2024.&nbsp;&nbsp;</h3>

Events

AstraZeneca Meet The Management: Weight Management Virtual Event Began At 10:00 am EST

<a href="https://www.bloomberg.com/news/articles/2024-11-04/astrazeneca-says-obesity-pill-well-tolerated-highly-competitive" title="https://www.bloomberg.com/news/articles/2024-11-04/astrazeneca-says-obesity-pill-well-tolerated-highly-competitive">https://www.bloomberg.com/news/articles/2024-11-04/astrazeneca-says-obesity-pill-well-tolerated-highly-competitive</a>

'AstraZeneca Says Experimental Obesity Pill Safe And Tolerable In Early-Stage Trial' - Bloomberg News; Shares Spike Higher

<a href="https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/">https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/</a>
All doses of Novo Nordisk&#39;s blockbuster diabetes and obesity treatments are <a href="https://dps.fda.gov/drugshortages/activeingredient/semaglutide-injection">listed as available</a> on the Food and Drug Administration&#39;s drug shortage list as of Wednesday, raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs.
Semaglutide, the scientific name for Novo&#39;s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times. With all doses now listed as available, the FDA may soon pull it off the list, depending on its conversations with Novo about whether the company can sufficiently meet demand going forward.
Over the past two years, patients seeking treatment have been turning to compounding pharmacies, which make cheaper copies of branded treatments and are legally allowed to do so only when the branded treatments are listed on the FDA&#39;s shortage list.&nbsp;

&nbsp;

AMGN

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

RHHBY

TERN

VANI

VKTX

Reported Earlier, 'Novo Nordisk's Ozempic and Wegovy, long in shortage, are now listed as available by FDA; It remains unclear how the update could affect patients as well as compounders' - STAT News

<a href="https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/azn-china-president-under-investigation-/8519003#:~:text=Leon%20Wang%2C%20Executive%20Vice%20President,General%20Manager%20of%20AstraZeneca%20China" title="https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/azn-china-president-under-investigation-/8519003#:~:text=Leon%20Wang%2C%20Executive%20Vice%20President,General%20Manager%20of%20AstraZeneca%20China">https://www.investegate.co.uk/announcement/rns/astrazeneca--azn/azn-china-president-under-investigation-/8519003#:~:text=Leon%20Wang%2C%20Executive%20Vice%20President,General%20Manager%20of%20AstraZeneca%20China</a>.

Management

AstraZeneca China President Under Investigation; China Operations Continue Under Current General Manager

Daiichi Sankyo And AstraZeneca Launch Three Phase 3 Trials For Datopotamab Deruxtecan-Based Combinations In Advanced Nonsquamous NSCLC; TROPION-Lung10, Lung14, And Lung15 Studies Target High PD-L1 Expression And EGFR Mutations With First Patients Dosed

WIIM

AstraZeneca shares are trading higher. The European Union approved the company's Fasenra as an add-on treatment as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis.

Earlier On Monday, The European Union Approved AstraZeneca's Fasenra (Benralizumab) As An Add-on Treatment For Adult Patients With Relapsing Or Refractory Eosinophilic Granulomatosis With Polyangiitis

On Friday,&nbsp;Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% <a target="_blank" href="https://www.benzinga.com/quote/SNY" rel="noreferrer noopener">in constant currency</a>.
The company <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-10-25-05-30-00-2969234" rel="noreferrer noopener">reported</a> third-quarter sales of 13.44 billion euros or $14.79 billion, beating the consensus of $13.97 billion.
Sales increased 12.3% year over year and 15.7% on constant currency, led by solid growth from Dupixent, Pharma launches, vaccines, and Opella.
The French drugmaker reported adjusted EPS of 2.86 euros or $1.57, up 12.2% (+17.6% on constant currency).
Sales of Dupixent, Sanofi&#8217;s blockbuster eczema drug, rose 23.8% to 3.48 billion euros.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease" rel="noreferrer noopener">FDA Approves Regeneron/Sanofi&#8217;s Blockbuster Dupixent For Smoker&#8217;s Lung Disease</a>
New pharma launches increased 67.1% to 727 million euros, led by Altuviiio (hemophilia&nbsp;drug), Nexviazyme (Pompe disease), and Rezurock (chronic graft-versus-host disease).
Vaccine sales were up 25.5% to 3.8 billion euros, boosted by the phasing of flu sales and by Beyfortus due to approved extra capacity.
Beyfortus (RSV) sales were 645 million euros, driven by early deliveries in the U.S. and rollout in several countries. In collaboration with AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), which is responsible for manufacturing, additional capacity enabled increased supply after a second external filling line was licensed.
Opella, Sanofi&#8217;s consumer healthcare business unit, generated sales of 1.3 billion euros, up 8%.
Guidance: Earlier this week, Sanofi updated its 2024 business EPS guidance to at least a low single-digit percentage at CER supported by the underlying strong business performance, reflecting the new scope of guidance <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41427490/sanofi-engages-in-exclusive-talks-with-us-private-equity-cd-r-for-its-consumer-health-business" rel="noreferrer noopener">excluding the Opella</a>.
Earlier the company expected business EPS to be stable <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39956385/sanofi-raises-2024-profit-outlook-on-strong-q2-earnings-blockbuster-drug-dupixent-sees-strong-dem" rel="noreferrer noopener">at constant currency</a>.
The company reaffirms that Dupixent will&nbsp;deliver around 13 billion euros in 2024 sales.
Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. 2024 vaccine sales are <a href="https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2024/2024-q3-2024-results/q3-2024-presentation-en.pdf" target="_blank" rel="noreferrer noopener">expected</a> to grow high single-digit compared to the earlier mid-single-digit range.
Sanofi forecasts Beyfortus sales for the fourth quarter to be similar to the third quarter.
Price Action: SNY stock is up 2.82% at $53.52 during the premarket session at the last check on Friday.
Image by HJBC via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41528255/googles-2b-investment-in-anthropic-under-scrutiny-uk-opens-competition-inquiry" target="_blank" rel="noreferrer noopener">Google&#8217;s $2B Investment in Anthropic Under Scrutiny, UK Opens Competition Inquiry</a></li>
</ul>

Earnings

Equities

Guidance

Movers

Trading Ideas

Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast

Monopar Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock is skyrocketing on Thursday.
The company agreed with AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Alexion for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41512666/monopar-announces-agreement-with-alexion-astrazeneca-rare-disease-for-late-stage-wilson-disease-dr" rel="noreferrer noopener">Wilson&#8217;s disease</a>.
Monopar will be responsible for all future global development and commercialization activities.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40833297/why-monopar-therapeutics-mnpr-stock-is-skyrocketing-today" rel="noreferrer noopener">Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today</a>
Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity in Monopar. Future payments are based on tiered royalties on net sales and pre-determined regulatory and sales milestones.
Wilson disease is a rare and progressive genetic condition in which the body&#8217;s pathway for removing excess copper is compromised. It affects one in 30,000 live births in the U.S.
Over time, the condition results in the build-up of toxic copper levels in the liver, brain, and other organs.
In April 2023, AstraZeneca <a target="_blank" href="https://wilsondisease.org/alexions-wilson-disease-drug-program-terminated/" rel="noreferrer noopener">decided</a> to terminate its ALXN1840 program as additional studies done to confirm the ALXN1840 mechanism of action did not achieve their endpoints, and they do not see a path forward to achieve approval from the FDA or European Medicines Agency.
The company&#8217;s decision was <a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2023/q1/Q1-2023-results-announcement.pdf" rel="noreferrer noopener">based</a> on feedback from regulators on the review of data from the Wilson Disease program, including the Phase 3 FoCus and two Phase 2 mechanistic trials.
In June 2022, the company shared detailed results from the FoCus Phase 3 trial of ALXN1840.
The study <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2022/alxn1840-shows-rapid-and-sustained-improvement-in-copper-mobilisation-from-tissues.html#" rel="noreferrer noopener">met</a> its primary endpoint, demonstrating three times greater copper mobilization from tissues compared to the standard of care (SoC) arm, including in patients treated previously for an average of 10 years. Topline data was <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2021/alxn1840-wilson-phase-iii-met-primary-endpoint.html#" rel="noreferrer noopener">shared</a> in August 2021.
In the trial, people taking ALXN1840 experienced rapid copper mobilization, with a response at four weeks and sustained through 48 weeks.
In patients who were symptomatic at baseline, neurological scores improved more for those treated with ALXN1840 than for those treated with SoC. However, no significant differences between treatment groups were observed at 48 weeks.
The company added that most patients in the trial had low symptom scores at baseline, so there was minimal room for total score improvement.
Price Action: MNPR stock is up 410.6% at $23.64 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41524917/marinus-pharmaceuticals-oral-seizure-drug-disappoints-in-late-stage-study-appoints-advisor-to-exp" target="_blank" rel="noreferrer noopener">Marinus Pharmaceuticals&#8217; Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options</a>.</li>
</ul>

Contracts

MNPR

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

<ul>
<li>Under the terms of the license agreement, Monopar will pay Alexion an upfront in the form of a cash payment and equity in Monopar. Future payments are based on tiered royalties on net sales and pre-determined regulatory and sales milestones.</li>
<li>Monopar will be responsible for all future global development and commercialization activities.</li>
</ul>

Monopar Therapeutics Has Entered Into An Agreement With Alexion, AstraZeneca Rare Disease For An Exclusive Worldwide License To ALXN-1840 (Bis-choline Tetrathiomolybdate) For Wilson Disease That Alexion Has Progressed Through Phase 3 Trial That Met Its Primary Endpoint

On Wednesday, Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)&nbsp;released its&nbsp;third-quarter sales report. Sales increased 9% year over year to 15.14 billion Swiss francs (~$17.5 billion).
The company&#8217;s pharmaceuticals division reported sales of 11.62 billion Swiss francs.
Roche&#8217;s top-performing asset was the multiple sclerosis drug Ocrevus; sales increased 11% to 1.69 billion Swiss francs.
Sales of Vabysmo, an age-related macular degeneration (AMD) treatment, <a target="_blank" href="https://assets.roche.com/f/176343/x/ad8d248346/appendix-tables-q3-2024.pdf" rel="noreferrer noopener">surged</a> 59% year over year to 1.02 billion Swiss francs.
Roche <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-10-23" rel="noreferrer noopener">reiterated</a> its business outlook, with the growth of around mid-single digits in group sales and the high-single-digit range for core earnings-per-share.
The European drugmaker <a target="_blank" href="https://assets.roche.com/f/176343/x/03b85564df/irp231024-a.pdf" rel="noreferrer noopener">axed</a> a mid-stage chronic cough program, RG6341.
Roche also axed a Phase 3 trial for divarasib in the second-line treatment of non-small cell lung cancer (NSCLC) and started a separate Phase 3 trial in NSCLC.
The company also removed Phase 2 trials for RG6416 (bepranemab) for Alzheimer&#8217;s, RG6139 tobemstomig monotherapy + combos for solid tumors, and RG7854/ RG6346/ RG6084 ruzotolimod/xalnesiran/PDL1 LNA for HBV infection.
Reuters noted that Roche is urging regulatory authorities to block Novo Holdings&#8217; proposed $16.5 billion acquisition of CDMO giant Catalent Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>), arguing that the deal would have wide-ranging negative effects on the industry.
Novo Holdings is the controlling shareholder of&nbsp;Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Last week, a coalition of unions, consumer groups, and public interest organizations wrote a letter to Lina Khan, Chair of the Federal Trade Commission (FTC), voicing strong opposition to the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41409503/after-us-senator-unions-urge-federal-trade-commission-to-block-novos-16-5b-acquisition-of-catalen" rel="noreferrer noopener">acquisition of Catalent</a>.
In the lawsuit, the coalition <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/byvrmlxkzpe/Consumer%20and%20Union%20Letter%20on%20Novo%20Catalent-10.17.24.pdf" rel="noreferrer noopener">contended</a> that although Novo and Eli Lilly are currently the only two competitors in the GLP-1 market, several other pharmaceutical and biotech companies—such as Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), Structure Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>), Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Sun Pharma, Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Roche, and AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)—have GLP-1 therapies in development.
These companies will require a CDMO partner to support the launch of their products in the coming years. Catalent is currently the only CDMO with significant experience collaborating with GLP-1 manufacturers.
Roche told Reuters that it is not directly impacted.
Reuters, citing Roche&#8217;s CEO Thomas Schinecker during a media call, highlights that limiting competition in this field would not be wise.
It adds that regulators could be making a mistake from an industry perspective. Schinecker elaborated in an analyst call that if companies start acquiring contract manufacturing organizations, market competition could decline.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41494373/whats-going-on-with-nvidia-stock-on-wednesday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Nvidia Stock On Wednesday?</a></li>
</ul>

Eurozone

CTLT

GPCR

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition

-&nbsp;Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo

IONS

Ionis And AstraZeneca's WAINZUA Recommended For EU Approval As First Self-Administered Treatment For hATTR-PN

DSKYF

AstraZeneca And Daiichi Sankyo's Enhertu (Trastuzumab Deruxtecan) Has Received Conditional Approval In China As Monotherapy For Adult Patients With Unresectable, Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Whose Tumors Have Activating HER2 Mutations And Who Have Received A Prior Systemic Therapy

Earlier this week, GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)&nbsp;reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability&nbsp;cases in the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41256992/gsk-resolves-majority-of-us-zantac-cases-with-2-2b-settlement-deal-stock-surges" rel="noreferrer noopener">U.S. state courts</a>.
These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company.
Under these agreements, GSK will&nbsp;<a target="_blank" href="https://otp.tools.investis.com/clients/uk/gsk/rns/regulatory-story.aspx?cid=410&amp;newsid=1873769" rel="noreferrer noopener">pay</a> up to $2.2 billion to resolve the claims, contingent upon eligibility and participation criteria.
Emma Walmsley, the CEO of GSK, may finally see relief from a major headache caused by legal cases surrounding the now-discontinued heartburn drug Zantac.
The update has reignited investor confidence. Financial Times highlighted that Deutsche Bank Research noted that this resolution makes GSK &#8220;investable again.&#8221;
The report further noted that legal issues have weighed heavily on GSK&#8217;s market value, particularly after a Morgan Stanley note in August 2022 projected the company&#8217;s liability for Zantac-related lawsuits to be between $3 billion and $27 billion.
This worst-case scenario wiped out nearly 13 billion pounds from GSK&#8217;s market capitalization.
Though the company&#8217;s market value had recovered by early 2023, investor anxiety resurfaced in June when a legal setback in Delaware, where most of the Zantac cases were filed, led to a one-day 6 billion pound drop in<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39594499/heartburn-drug-zantac-litigation-gsk-and-other-pharma-giants-face-trial-over-cancer-claims" rel="noreferrer noopener"> GSK&#8217;s market cap</a>.
The report adds that investors are now shifting their focus to GSK&#8217;s broader performance and long-standing concerns about its drug pipeline.
GSK has set an ambitious target of increasing its sales to over 38 billion pounds ($49.6 billion) by 2031, up from 30.3 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36866039/gsk-upgrades-long-term-outlook-after-q4-performance-shingrix-vaccine-and-newly-launched-rsv-vacci" rel="noreferrer noopener">pounds in 2023</a>.
However, the market remains skeptical, especially compared to AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) 2030 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38936595/astrazeneca-targets-ambitious-80b-in-total-revenue-by-2030-through-pipeline-expansion" rel="noreferrer noopener">sales goal of $80 billion</a>.
Projections suggest GSK may fall short, with estimated 2030 sales of £35.7 billion. The report noted that a significant challenge facing GSK is the expiration of patents on key HIV treatments containing dolutegravir starting in 2028.
While Walmsley has pointed to the company&#8217;s strength in vaccines, recent developments have cast doubt on this strategy, the FT <a target="_blank" href="https://www.ft.com/content/ff4e97f8-ba2e-4741-ac4b-f1c62d6dba21" rel="noreferrer noopener">notes</a>. GSK&#8217;s RSV vaccine, Arexy, initially achieved blockbuster status, but a U.S. health committee&#8217;s decision to narrow its recommended age <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41278571/gsk-pfizer-face-declining-respiratory-syncytial-virus-vaccine-sales-due-to-narrow-age-recommendat" rel="noreferrer noopener">group has dampened expectations</a>.
Additionally, the global performance of GSK&#8217;s shingles vaccine has not offset a slowdown in the U.S.
Though the Zantac legal burden has lessened, GSK&#8217;s challenges with its product pipeline remain unresolved.
Price Action: GSK stock is down 0.62% at $38.97 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41291876/chrysler-parent-stellantis-kicks-off-ceo-search-as-carlos-tavares-plans-2026-retirement" target="_blank" rel="noreferrer noopener">Chrysler Parent Stellantis Kicks Off CEO Search As Carlos Tavares Plans 2026 Retirement</a></li>
</ul>
Photo by ParentingPatch via <a href="https://commons.wikimedia.org/wiki/File:Zantac_Pill_and_Pill_Pack.JPG">Wikimedia Commons</a>

GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain

AstraZeneca Reports 9.9% Passive Stake In Conduit Pharmaceuticals

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare &amp; Medicaid Services (CMS), has released a Request for Information (RFI) regarding a new initiative to lower prescription drug costs for Medicare recipients.
The Medicare $2 Drug List Model, developed under President Biden&#8217;s Executive Order 14087, seeks to offer certain generic drugs for a fixed copayment of no more than $2 per month.
This initiative targets commonly prescribed drugs for conditions like high cholesterol and high blood pressure.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Might Be Among 2027 Medicare Price Negotiation Targets</a>.
The Center for Medicare and Medicaid Innovation (Innovation Center) has designed the Medicare $2 Drug List Model to test whether simplifying access to affordable, clinically important generics will improve health outcomes, improve medication adherence, and boost overall satisfaction with the Medicare Part D program.
These drugs, which would not be subject to typical utilization management requirements, could be available at all participating pharmacies as early as January 2027.
The initial list of <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-next-step-proposed-model-lower-prescription-drug-costs-people" rel="noreferrer noopener">drugs</a> for the $2 Drug List Model has been carefully developed through a rigorous process. It incorporates input from physicians, pharmacists, and health policy experts to ensure that the selected medications address common conditions for Medicare recipients.
The concept of a fixed-cost drug list is not new, with many retail pharmacies already offering generic medications at low, standardized prices.
However, the Medicare $2 Drug List Model will be tailored specifically to Medicare recipients.
Last week,&nbsp;the HHS released final guidance for the second &nbsp;Medicare Drug Price <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Negotiation Program cycle</a>.
This initiative&nbsp;<a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-releases-final-guidance-second-cycle-historic-medicare-drug-price-negotiation-program" rel="noreferrer noopener">aims</a> to provide lower drug prices starting in 2026 and 2027.
The first round of negotiations focused on ten specific drugs. When the new prices take effect in 2026, Medicare recipients should save approximately $1.5 billion in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">out-of-pocket costs</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41256266/is-the-iphone-losing-its-buzz-among-teens-piper-sandler-finds-out" target="_blank" rel="noreferrer noopener">Is The iPhone Losing Its Buzz Among Teens? Piper Sandler Finds Out</a></li>
</ul>
Image via Shutterstock

Government

BMRN

GILD

REGN

VRTX

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients

AstraZeneca (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azn#NASDAQ">AZN</a>) announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disruptor for helping patients with dyslipidaemia.
The latest agreement is likely to strengthen AstraZeneca&#39;s cardiovascular pipeline, which is being studied for treating various cardiovascular diseases.
Year to date, shares of AstraZeneca have rallied 14.1% compared with the industry&#39;s rise of 18.5%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fa/80674.jpg?v=23295027" />
Image Source: Zacks Investment Research
<h2>More on AZN&#39;s Latest Agreement</h2>
Per the deal, AZN will make an upfront payment of $100 million to CSPC. The company is also entitled to pay up to $1.92 billion for further development and commercialization milestones plus tiered royalties to CSPC.
Per the latest agreement with CSPC, AstraZeneca will gain access to the latter&#39;s pre-clinical candidate, YS2302018, an oral Lp(a) disruptor, and develop the same for various cardiovascular diseases. The company will develop YS2302018 alone or in combination studies, including with the oral small molecule PCSK9 inhibitor, AZD0780.
Discovered by CSPC, YS2302018 has been shown to effectively prevent the formation of Lp(a), a form of low-density lipoprotein&nbsp;that plays a key role in transporting cholesterol in the bloodstream.
Per the company, the addition of YS2302018 to AZN&#39;s cardiovascular pipeline might help patients to more effectively manage their dyslipidaemia and cardiometabolic diseases.
<h2>AZN&#39;s Airsupra Meet Goal in BATURA Study</h2>
In a separate press release, AstraZeneca announced positive data from the phase IIIb BATURA study, which evaluated its pressurized metered-dose inhaler (pMDI), Airsupra (albuterol/budesonide).
Data from the study showed that treatment with Airsupra led to a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms versus as-needed albuterol in patients with intermittent or mild persistent asthma. This was the primary endpoint of the BATURA study.
Airsupra is approved for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and above in the United States. It is the first and only anti-inflammatory rescue medication for the given condition.
<h2>AZN&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
AstraZeneca currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), ADMA Biologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>), each sporting a Zacks Rank #1 (Strong Buy) at present. In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share estimates for 2025 have improved from $5.38 to $5.86. Year to date, shares of ANIP have increased 1.3%.
ANIP&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for ADMA Biologics&#39; 2024 earnings per share have increased from 35 cents to 49 cents. Earnings per share estimates for 2025 have improved from 53 cents to 64 cents. Year to date, shares of ADMA have surged 346.5%.
ADMA&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 105.63%.
In the past 60 days, estimates for Alnylam&#39;s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per share estimates for 2025 have narrowed from 34 cents to 27 cents. Year to date, shares of ALNY have rallied 39.4%.
ALNY&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.
<a href="https://www.zacks.com/stock/news/2347767/astrazeneca-inks-agreement-to-boost-cardiovascular-pipeline?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2347767">To read this article on Zacks.com click here.</a>

Earnings Beats

Mid Cap

Small Cap

Analyst Ratings

ADMA

ALNY

ANIP

AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 150 points on Monday.
The Dow traded down 0.97% to 41,940.43 while the NASDAQ fell 0.89% to 17,976.85. The S&amp;P 500 also fell, dropping, 0.77% to 5,707.03.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41206375/jim-cramer-ast-spacemobile-is-just-too-hot-recommends-buying-this-tech-stock">Jim Cramer: AST SpaceMobile Is &#8216;Just Too Hot,&#8217; Recommends Buying This Tech Stock</a>
Leading and Lagging Sectors Energy shares jumped by 0.6% on Monday.
In trading on Monday, utilities shares dipped by 1.7%.
Top Headline
AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to advance the development of an early-stage, novel small-molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) shares shot up 328% to $31.73 after the company announced topline results from the Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab in patients with SMA. The study achieved its primary endpoint.</li>
<li>Shares of Arcadium Lithium PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) got a boost, surging 32% to $4.06 after the company announced that it has been approached by Rio Tinto regarding a potential acquisition.</li>
<li>Duckhorn Portfolio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAPA#NASDAQ">NAPA</a>) shares were also up, gaining 104% to $10.99 after the company reported better-than-expected fourth-quarter financial results. Also, the company announced it into a definitive agreement to be acquired by private equity funds managed by Butterfly Equity.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Trevena, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares dropped 46% to $2.50 after the company announced it received a Nasdaq delisting notification.</li>
<li>Shares of Heritage Insurance Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NYSE">HRTG</a>) were down 25% to $9.09.</li>
<li>Universal Insurance Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UVE#NYSE">UVE</a>) was down, falling 19% to $17.12.</li>
</ul>
Commodities In commodity news, oil traded up 3.6% to $77.02 while gold traded down 0.1% at $2,666.10.
Silver traded down 1.1% to $32.035 on Monday, while copper fell 0.2% to $4.5635.
Euro zone
European shares closed mostly higher today. The eurozone's STOXX 600 rose 0.18%, Germany's DAX fell 0.09% and France's CAC 40 climbed 0.46%. Spain's IBEX 35 Index rose 0.50%, while London's FTSE 100 rose 0.28%.
Retail sales in the Eurozone rose 0.2% month-over-month in August compared to a revised flat reading in the previous month. The Halifax House Price Index in the UK rose 4.7% year-over-year in September compared to a 4.3% gain in August. Factory orders in Germany declined by 5.8% month-over-month in August.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 1.80%, Hong Kong's Hang Seng Index gaining 1.60% and India's BSE Sensex dipping 0.78%.
Foreign exchange reserves in Singapore fell to SGD 499.7 billion in September compared to SGD 501.3 billion a month ago. The index of leading economic indicators in Japan fell to 106.7 in August versus a final reading of 109.3 in the prior month, while index of coincident economic indicators declined to 113.5 in August compared to a final reading of 117.2 month ago.
Economics
Data on consumer credit for August will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41205686/how-to-earn-500-a-month-from-pepsico-stock-ahead-of-q3-earnings">How To Earn $500 A Month From PepsiCo Stock Ahead Of Q3 Earnings</a></li>
</ul>
<a href="https://www.benzinga.com/news/earnings/24/10/41205686/how-to-earn-500-a-month-from-pepsico-stock-ahead-of-q3-earnings">&nbsp;</a>

Commodities

Intraday Update

ALTM

HRTG

NAPA

SRRK

TRVN

Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge

Markets outside the United States don't always move in sync with domestic trends, which means adding international stocks can help reduce volatility and spread risk. Thus, investors looking to diversify their portfolio can consider investing in fundamentally sound companies like SAP SE (SAP), AstraZeneca (AZN), and Alibaba Group (BABA) for potential returns. Read on… When it comes to investing, many people think that simply spreading their money across a few different companies is enough for diversification. However, true diversification is more nuanced. Recent global economic and geopolitical challenges have raised important questions about how much <a href="https://www.tiaa.org/public/invest/services/wealth-management/perspectives/why-international-stocks-still-make-sense">international exposure</a> investors should have in their portfolios.
While U.S. stocks are influenced mainly by domestic factors, international stocks tap into diverse economic trends across different regions that can enhance returns and mitigate risks. Below, I have highlighted three global stocks, namely, SAP SE (<a href="https://stocknews.com/stock/SAP/">SAP</a>), AstraZeneca PLC (<a href="https://stocknews.com/stock/AZN/">AZN</a>), and Alibaba Group Holding Limited (<a href="https://stocknews.com/stock/BABA/">BABA</a>), that provide exposure to international equities for portfolio diversification by offering opportunities in expanding economies and emerging markets.
As countries focus on building their own capabilities and becoming less reliant on foreign markets, new opportunities are emerging. This shift can lead to greater competition and economic independence, meaning that while the U.S. economy might struggle, some international markets could be booming, and vice versa. Such diversification can be beneficial for long-term investors.
Currently, inflation levels across many countries are hovering close to central bank targets, which could pave the way for easier monetary policies. Moreover, the global economy has shown resilience, with growth expected to maintain a steady pace of <a href="https://www.imf.org/en/Blogs/Articles/2024/10/22/as-inflation-recedes-global-economy-needs-policy-triple-pivot#:~:text=Growth%20is%20projected%20to%20hold%20steady%20at%203.2%20percent%20in,often%20tied%20to%20intensifying%20conflicts.">3.2% in 2024</a> and 2025. Emerging markets, in particular, are projected to grow at around 4.2% this year and next, buoyed by strong performance in emerging Asia.
In addition, emerging market equities have recently outperformed their developed market counterparts, achieving <a href="https://www.lazardassetmanagement.com/research-insights/outlooks/emerging-markets">gains of 8.7%</a> compared to 6.4%. This marks a significant trend, as it is the first time since 2020 that emerging markets have outperformed for two consecutive quarters.
Considering these conducive trends, let's discuss the fundamentals of the featured stocks in detail:
SAP SE (<a href="https://stocknews.com/stock/SAP/">SAP</a>)
SAP is a Germany-based company that offers enterprise application software. It operates through three segments: Applications, Technology &amp; Services; the SAP Business Network; and the Customer Experience.
On September 12, the company completed its acquisition of WalkMe Ltd. (<a href="https://stocknews.com/stock/WKME/">WKME</a>) for $1.5 billion in an all-cash deal. WKME's digital adoption platform will enhance SAP's Business Transformation Management portfolio, including SAP Signavio and SAP LeanIX, by improving workflow execution and user experience. Its AI technology will also power SAP's Joule copilot, offering context-aware assistance to boost workflow productivity.
SAP's total revenue for the third quarter (ended September 30, 2024) increased 9.4% year-over-year to €8.47 billion ($9.16 billion). Its gross profit grew 10.2% from the year-ago value to €6.21 billion ($6.72 billion).
The company's cash inflow from operating activities amounted to €1.47 billion ($1.59 billion), representing a 31.2% improvement from the same period last year. Also, its <a href="https://www.investopedia.com/terms/f/freecashflow.asp">free cash flow</a> stood at €1.25 billion ($1.35 billion), up 44.3% year-over-year.
Analysts expect SAP's revenue for the fourth quarter (ending December 2024) to grow 7.3% year-over-year to $9.86 billion, while its EPS for the same period is estimated to come in at $1.51. Also, it topped the revenue estimates in three of the trailing four quarters.
The stock has gained 77.8% over the past year to close the last trading session at $237.69.
SAP's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
It has a B grade for Stability, Sentiment, and Quality. Out of 132 stocks in the <a href="https://stocknews.com/category/software-application/">Software – Application</a> industry, SAP is ranked #27. <a href="https://stocknews.com/stock/SAP/">Click here</a> to see SAP's Growth, Value, Momentum, and Sentiment ratings.
AstraZeneca PLC (<a href="https://stocknews.com/stock/AZN/">AZN</a>)
Headquartered in Cambridge, the United Kingdom, AZN is a renowned biopharmaceutical company focusing on discovering, developing, manufacturing, and commercializing prescription medicines. Its marketed products treat oncology, COVID-19, respiratory, cardiovascular, renal, and metabolism diseases, etc.
On June 4, AZN acquired Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specializing in next-generation radioconjugates (RCs). The acquisition strengthens the company's oncology portfolio with Fusion's innovative RC pipeline, including FPI-2265 for metastatic castration-resistant prostate cancer (mCRPC). It also enhances AZN's expertise in RCs and expands its R&amp;D, manufacturing, and supply chain capabilities while bolstering its presence in Canada.
For the second quarter that ended June 30, 2024, AZN's total revenue increased 13.3% year-over-year to $12.94 billion, while its gross profit rose 13.7% from the year-ago value to $10.76 billion. The company's profit after tax and EPS amounted to $1.93 billion and $1.24, representing increases of 5.9% and 6% from the prior-year quarter, respectively. In addition, its operating profit stood at $2.75 billion, up 11.8% year-over-year.
The consensus EPS estimate of $1.05 for the third quarter (ending September 2024) represents a 20.9% improvement year-over-year. The consensus revenue estimate of $13.11 billion for the same period indicates a 14.1% increase from the prior-year period. The company has an impressive surprise history; it surpassed the consensus revenue estimates in three of the trailing four quarters.
AZN's shares have gained 16.2% over the past year to close the last trading session at $75.05.
It's no surprise that AZN has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. It has an A grade for Growth and Stability and a B for Value and Quality. Among 163 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, it is ranked #7.
In addition to the POWR Ratings we've stated above, we also have AZN's ratings for Momentum and Sentiment. Get all AZN ratings <a href="https://stocknews.com/stock/AZN/">here</a>.
Alibaba Group Holding Limited (<a href="https://stocknews.com/stock/BABA/">BABA</a>)
Based in Hangzhou, China, BABA offers technology infrastructure and marketing reach to help merchants, brands, and retailers connect with international users and customers. Its segments include China Commerce; International Commerce; Local Consumer Services; Cainiao; Cloud; Digital Media and Entertainment; Innovation Initiatives and Others.
On September 5, BABA partnered with Mastercard Incorporated (<a href="https://stocknews.com/stock/MA/">MA</a>) and Cardless to introduce a co-branded credit card that rewards businesses for cross-border and domestic purchases on Alibaba.com. The partnership would simplify shopping, boost customer loyalty, and strengthen BABA's global presence.
For the fiscal 2025 first quarter that ended June 30, 2024, BABA's revenue increased 3.9% year-over-year to $33.47 billion. Its income from operations amounted to $4.95 billion. Plus, the company reported its adjusted EBIDTA at $6.20 billion for the quarter. Moreover, its non-GAAP net income and non-GAAP EPS came in at $5.60 billion and $0.28 for the quarter, respectively.
Analysts expect BABA's revenue for the fiscal third quarter ending December 2024 to increase 9% year-over-year to $39.45 billion. Likewise, its EPS for the ongoing quarter is expected to grow by 3.5% from the prior year to $2.73.
Shares of BABA have gained 30.5% over the past six months and 25.7% year-to-date to close the last trading session at $97.42.
BABA's POWR Ratings reflect its positive outlook. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system.
It also has a B grade for Quality. In the 41-stock A-rated <a href="https://stocknews.com/category/china/">China</a> industry, it is ranked #18. To see BABA's Growth, Value, Momentum, Stability, and Sentiment ratings, <a href="https://stocknews.com/stock/BABA/">click here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
SAP shares . Year-to-date, SAP has gained 55.15%, versus a 22.97% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/sap-azn-baba-wkme-ma-3-global-stocks-to-diversify-your-portfolio/>3 Global Stocks to Diversify Your Portfolio</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Global Stocks to Diversify Your Portfolio

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £1...

AstraZeneca (AZN) Receives a Buy from J.P. Morgan

AstraZeneca (AZN) said Monday at the ObesityWeek conference in San Antonio, Texas that its experimental obesity pill was well-tolerated by patients...

AstraZeneca says experimental obesity pill 'competitive,' Bloomberg reports

After AstraZeneca (AZN) presented data at the ObesityWeek conference, Deutsche Bank said the company's oral small molecule GLP1 drug – AZD5004 – lo...

AstraZeneca oral GLP1 looks to be trailing Eli Lilly's, says Deutsche Bank

Eli Lilly ($LLY) is falling today due to reports of progress from competitors. The pharmaceutical producer has struggled recently as its share of t...

Eli Lilly (NYSE:LLY) Stock Falls as Competitors Report Progress

A bit of earnings and election jitters roiled the market last week reordering  the leaderboard in biopharma stocks.

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £140.0...

Barclays Reaffirms Their Buy Rating on AstraZeneca (AZN)

In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)

Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price target at ...

AstraZeneca's Promising Obesity Treatment Advances Justify Buy Rating: Analyst Report

AZNCF

BABA

WKME

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

MRNA

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Screenshot 2023-07-10 at 5.56.06 PM

GNPX

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Press Releases

Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy

How Cosmos Health's Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma

AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial

Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

RCUS

TYO:4568

Axsome Therapeutics

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

AstraZeneca

AstraZeneca (AZN) オプション

AstraZeneca (NASDAQ:AZN) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル